Reversine: Benchmark Aurora Kinase Inhibitor for Cancer C...

2026-03-15

Reversine: Benchmark Aurora Kinase Inhibitor for Cancer Cell Cycle Research

Executive Summary: Reversine (6-N-cyclohexyl-2-N-(4-morpholin-4-ylphenyl)-7H-purine-2,6-diamine) is a potent, small molecule inhibitor of Aurora kinases A, B, and C, with IC₅₀ values of 150 nM, 500 nM, and 400 nM, respectively, and is supplied by APExBIO (product page) [1]. It is cell-permeable, disrupts mitotic regulation, and induces apoptosis and dedifferentiation in vitro and in vivo [2]. Reversine's specificity and solubility in DMSO and ethanol make it suitable for high-fidelity experimental workflows [1]. It is validated in cervical cancer and recommended for research use only [3]. Recent integrative omics studies highlight Aurora kinase pathways as precision targets in oncology [4].

Biological Rationale

Aurora kinases (A, B, C) are serine/threonine kinases essential for mitotic progression, including centrosome maturation, spindle assembly, chromosomal alignment, and cytokinesis [1,4]. Dysregulation of these kinases is implicated in chromosomal instability, tumorigenesis, and poor prognosis in multiple cancer types [4]. Selective inhibition of Aurora kinases can arrest mitotic progression and trigger apoptosis, providing a mechanistic basis for targeted cancer therapy [1,5]. Proteogenomic analyses, such as those in lung adenocarcinoma, have identified Aurora kinase signaling as a vulnerability in tumors with high genomic instability [4].

Mechanism of Action of Reversine

Reversine is a synthetic purine analogue that competitively inhibits the ATP-binding sites of Aurora kinases A, B, and C [1]. Its nanomolar-range IC₅₀ values—150 nM (A), 500 nM (B), and 400 nM (C)—have been established using in vitro kinase assays [1]. The compound impedes phosphorylation events necessary for spindle assembly and chromosome segregation, resulting in cell cycle arrest at G2/M and induction of apoptosis [2,3]. In murine myoblasts, reversine induces dedifferentiation, while in cancer cell lines (HeLa, U14, Siha, Caski, C33A), it suppresses proliferation by downregulating Aurora kinase expression [2].

Evidence & Benchmarks

Reversine inhibits mitotic progression in HeLa and other cervical cancer cell lines, with significant antiproliferative effects in vitro (Satpathy et al., 2025).
IC₅₀ values for Aurora kinases: 150 nM (A), 500 nM (B), 400 nM (C), determined by kinase activity assays at pH 7.5, 25°C (APExBIO product data).
Reversine induces apoptosis in cervical cancer xenograft models, especially when combined with aspirin, leading to reduced tumor volume and weight in murine systems (Satpathy et al., 2025).
Solubility: ≥19.65 mg/mL in DMSO, ≥6.69 mg/mL in ethanol (with gentle warming and ultrasonic treatment); insoluble in water (APExBIO).
Proteogenomic screens nominate Aurora kinase inhibitors as therapeutic agents for genomically unstable lung adenocarcinoma subtypes (Satpathy et al., 2025).

For more detailed scenario-driven applications and troubleshooting, see this scenario-based guide, which this article extends by offering a molecular mechanism focus and cross-tumor relevance.

Applications, Limits & Misconceptions

Reversine is widely used in cancer research to probe mitotic checkpoints, chromosome segregation, and the induction of apoptosis in vitro and in vivo [1,3]. Its application includes:

Studying cell cycle arrest and checkpoint signaling in tumor cell lines.
Evaluating anti-proliferative and pro-apoptotic effects in xenograft models.
Screening drug synergies, e.g., with aspirin, for enhanced tumor suppression.
Dissecting Aurora kinase pathway dependencies in omics-driven cancer subtypes (Satpathy et al., 2025).

This article clarifies and updates the mechanistic insights presented in this mechanistic review by integrating recent proteogenomic findings.

Common Pitfalls or Misconceptions

Not suitable for diagnostic or clinical therapeutic use: Reversine is intended strictly for research use.
Insoluble in aqueous buffers: Use DMSO or ethanol as solvents; water-based solutions lead to precipitation and assay failure.
Degradation upon long-term solution storage: Prepare fresh solutions and use promptly; avoid repeated freeze-thaw cycles (APExBIO).
Non-selectivity at high concentrations: Off-target kinase inhibition may occur above recommended working concentrations.
Not effective in non-Aurora kinase-dependent tumor models: Efficacy is limited in cell lines/tumors lacking Aurora kinase overexpression or dependency.

For practical troubleshooting and comparative product insights, see this application-focused benchmark, which this article extends by mapping specific mechanistic and solubility parameters.

Workflow Integration & Parameters

Reversine is supplied as a solid by APExBIO (SKU A3760) and should be stored at -20°C [1]. Solubilization is recommended in DMSO (≥19.65 mg/mL) or ethanol (≥6.69 mg/mL with warming and ultrasound); avoid water [1]. Solutions are not stable for long-term storage—freshly prepare before use. Typical in vitro working concentrations range from 50 nM to 2 μM, depending on cell type and assay [1,2]. For in vivo work, dosing regimens should be optimized based on animal weight and tumor model, referencing published protocols [2]. Always ensure cell viability and solvent controls. Cross-reference with the APExBIO product page for updated handling and safety information.

Conclusion & Outlook

Reversine is a validated, cell-permeable Aurora kinase inhibitor with established efficacy in cancer research, particularly for dissecting mitotic regulation and apoptosis induction [1-4]. Its well-characterized specificity, solubility, and research-grade formulation enable robust workflows in both in vitro and in vivo systems. Future directions include further integration with proteogenomic stratification of cancer subtypes and combination therapy screens. For researchers requiring high-precision modulation of the Aurora kinase signaling pathway, Reversine from APExBIO represents a best-in-class solution.

References: